NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical lead drug candidate NV-387 demonstrated potent antiviral effects against the Measles virus in both cell culture studies and a humanized animal model. The treatment extended survival in infected mice by 130%, increasing from 7.4 to 17 days, while significantly protecting lung tissue from viral and immune-related damage. This finding represents a significant advancement in antiviral research, particularly given the current absence of any approved drug for Measles treatment.
The drug's dual mechanism of action—direct viral suppression combined with mitigation of systemic and lung inflammation—resulted in reduced lung plaques, slower disease progression, and improved overall health outcomes in treated animals. This comprehensive approach addresses both the viral infection itself and the damaging inflammatory response that often contributes to severe disease outcomes. The lung-protective effects observed in the studies suggest NV-387 could potentially reduce the long-term complications associated with Measles infection, including pneumonia and other respiratory sequelae.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy, with its technology based on intellectual property from TheraCour Pharma, Inc. The company's business model involves licensing technology from TheraCour for specific application verticals of specific viruses, as detailed on their corporate website at https://www.nanoviricides.com. NV-387 represents the company's lead drug candidate, which they plan to develop as a treatment for multiple respiratory viral infections including RSV, COVID, Long COVID, and Influenza, in addition to MPOX/Smallpox infections.
The implications of these findings extend beyond Measles treatment alone. The demonstrated broad-spectrum antiviral potential of NV-387 suggests it could address multiple viral threats with a single therapeutic approach. This is particularly relevant given the company's extensive licensing portfolio covering numerous viral diseases, including Human Immunodeficiency Virus, Hepatitis B and C, Rabies, Herpes Simplex Virus, and various influenza strains. The company holds worldwide exclusive perpetual licenses for these therapeutic areas through its relationship with TheraCour.
Currently, NanoViricides is focused on advancing NV-387 into Phase II human clinical trials. The successful preclinical results against Measles add to the growing body of evidence supporting the drug's potential across multiple viral indications. For investors and stakeholders seeking additional information, the company maintains a newsroom at https://ibn.fm/NNVC where updates are regularly posted. The development pathway for any pharmaceutical product remains lengthy and capital-intensive, with no guarantees of successful clinical outcomes, but these recent findings represent an important milestone in antiviral drug development.
